Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DE-126 versus latanoprost for 24-hour intraocular pressure lowering in primary open-angle glaucoma or ocular hypertension
2020-004836-93Phase 2Completed
- Sponsor
- Santen Pharmaceutical
- Start
- Mar 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of sepetaprost in open-angle glaucoma (OAG) and ocular hypertension (2 arms), sponsored by Santen Pharmaceutical. Primary endpoint: Primary efficacy endpoint. Started Mar 2021; status: completed.
02
Drugs
sepetaprost
03
Conditions
open-angle glaucoma (OAG)ocular hypertension
Beyond the preview
Go deeper on 2020-004836-93.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-004836-93.